Table 1. Risk of female gonadotoxicity of various antineoplastic agents (modified from Pentheroudakis et al., 2010; Christinat & Pagani, 2012)
  High risk (permanent amenorrhoea in > 80% of exposed women) Intermediate risk (permanent amenorrhoea between 20% and 80% of exposed women) Low risk (permanent amenorrhoea in < 20% of exposed women) Risk not established
Single agents Cyclophosphamide
Busulfan
Melphalan
Chlorambucil
Dacarbazine
 
Procarbazine
Ifosfamide
Thiotepa 		Anthracyclines
Cisplatin
Carboplatin
Ara-C (cytarabine) 		Methotrexate
Bleomycin
5-Fluorouracil
Actinomycin-D
Vinca alkaloids
 
Mercaptopurine
Etoposide
Fludarabine 		Taxanes
Oxaliplatin
Irinotecan
Monoclonal antibodies
Tyrosine-kinase inhibitors
Combined agents and radiotherapy Nitrogen mustard
 
High-dose cyclophosphamide/busulfan and haemopoietic stem cell transplantation
 
Ovarian irradiation
 
CMF, CAF, CEF ×6 in women < 40 years
 CMF, CAF, CEF × 6 in women 30-39 years
 
 
 
 
 
AC, EC × 4 in women > 40 years 		ABVD
 
CMF, CEF, CAF × 6 in women < 30 years
 
MF
 
CHOP, CVP
 
Protocols for acute myeloid leukemia, acute lymphoid leukemia
 
AC ×4 in women < 40 years 		 
AC = doxorubicin + cyclophosphamide; CAF = cyclophosphamide + doxorubicin + fluorouracil;
CEF = cyclophosphamide + epirubicin + fluorouracil; CMF = cyclophosphamide + methotrexate + fluorouracil;
MF = methotrexate + fluorouracil; EC = epirubicin + cyclophosphamide;
CHOP = cyclophosphamide + doxorubicin + vincristine + prednisolone;
CVP = cyclophosphamide + vincristine + prednisone; ABVD = adriamycin + bleomycin + vinblastine + dacarbazine.